Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sagimet Biosciences, Inc. Class A ( (SGMT) ) has shared an update.
On April 27, 2026, Sagimet Biosciences, Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share, expected to generate net proceeds of about $164.5 million after underwriting discounts and commissions. The capital raise, managed by a syndicate of investment banks under an effective shelf registration, is intended to fund a Phase 3 clinical trial of denifanstat in acne, advance TVB-3567 through Phase 2 topline results, progress a topical FASN inhibitor to an IND filing, and support general corporate and clinical development needs, reinforcing Sagimet’s ability to advance its pipeline and sustain operations.
On April 27, 2026, Sagimet Biosciences, Inc. finalized an underwriting agreement for a major stock offering to bolster funding for its dermatology-focused drug pipeline. The transaction is expected to provide $164.5 million in net proceeds, strengthening the company’s financial position to execute late-stage trials, progress additional candidates, and cover broader operating expenses.
The most recent analyst rating on (SGMT) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.
Spark’s Take on SGMT Stock
According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.
The score is held back primarily by weak financial performance (widening losses and sustained cash burn) and limited valuation support from a negative P/E and no dividend. Offsetting these are improving technical momentum and favorable recent corporate updates around clinical/regulatory progress and liquidity/runway strengthening.
To see Spark’s full report on SGMT stock, click here.
More about Sagimet Biosciences, Inc. Class A
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors for dermatologic and other indications. Its pipeline includes denifanstat for acne, the candidate TVB-3567, and a topical FASN inhibitor formulation, targeting unmet needs in skin and related diseases.
Average Trading Volume: 1,319,564
Technical Sentiment Signal: Buy
Current Market Cap: $187.6M
Learn more about SGMT stock on TipRanks’ Stock Analysis page.